<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0186-4866</journal-id>
<journal-title><![CDATA[Medicina interna de México]]></journal-title>
<abbrev-journal-title><![CDATA[Med. interna Méx.]]></abbrev-journal-title>
<issn>0186-4866</issn>
<publisher>
<publisher-name><![CDATA[Edición y Farmacia S.A. de C.V.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0186-48662018000200009</article-id>
<article-id pub-id-type="doi">10.24245/mim.v34i2.1613</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Hiperuricemia e hipertensión arterial sistémica: ¿cuál es la relación?]]></article-title>
<article-title xml:lang="en"><![CDATA[Hyperuricemia and systemic arterial hypertension: what is the relationship?]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vázquez-Ávila]]></surname>
<given-names><![CDATA[José Armando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Zetina-Martínez]]></surname>
<given-names><![CDATA[Michael]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Duarte-Mote]]></surname>
<given-names><![CDATA[Jesús]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,ISEM  ]]></institution>
<addr-line><![CDATA[Estado de México ]]></addr-line>
</aff>
<aff id="Af2">
<institution><![CDATA[,ISEM Estado de México ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2018</year>
</pub-date>
<volume>34</volume>
<numero>2</numero>
<fpage>278</fpage>
<lpage>287</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0186-48662018000200009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0186-48662018000200009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0186-48662018000200009&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El ácido úrico es producto final del metabolismo de las purinas, transformadas finalmente a ácido úrico. No existe definición universal de hiperuricemia, en la práctica, el punto de corte es a partir de 6.8 mg/dL en plasma. Estudios experimentales han demostrado una correlación positiva lineal entre la presión arterial y las concentraciones de ácido úrico, así como disminución de las cifras tensionales al administrar tratamiento hipouricemiante con alopurinol. Se han identificado numerosos mecanismos a través de los cuales la hiperuricemia puede causar hipertensión: reducción de las concentraciones de óxido nítrico endotelial, estimulación de estrés oxidativo, expresión en las células de músculo liso del endotelio vascular de receptor URAT-1, activación del eje renina angiotensina, estimulación de la proliferación de músculo liso vascular, además, favorece la enfermedad microvascular renal. La evidencia reciente ha aportado nuevo conocimiento acerca de los múltiples mecanismos a través de los cuales el ácido úrico tendría un papel preponderante en la hipertensión arterial sistémica y en múltiples alteraciones metabólicas; sin embargo, hace falta desarrollar estudios clínicos a gran escala, bien diseñados, que comprueben de manera más contundente estas teorías, antes de considerar tratamientos enfocados en el manejo de la hiperuricemia asintomática en la práctica clínica diaria.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Uric acid is the end product of purine metabolism, ultimately converted to uric acid. There is no universal definition of hyperuricemia, in practice, the cutoff point is from 6.8mg/dL in plasma. The relationship between hyperuricemia and hypertension has been demonstrated in many experimental studies. Experimental studies have shown a linear positive correlation between blood pressure and uric acid levels, as well as a decrease in blood pressure figures with therapy with allopurinol. Numerous mechanisms have been identified through which hyperuricemia can cause hypertension: reduction of endothelial nitric oxide levels, stimulation of oxidative stress, expression in smooth muscle cells of the vascular endothelium of URAT-1 receptor, activation of the renin-angiotensin axis, stimulation of vascular smooth muscle proliferation also favors the development of renal microvascular disease. Recent evidence has provided new insight into the multiple mechanisms through which UA would play a major role both in systemic arterial hypertension and in multiple metabolic alterations; however, large-scale, well-designed clinical studies are needed, which prove more conclusively these theories, before considering therapies focused on the management of asymptomatic hyperuricemia in daily clinical practice]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Ácido úrico]]></kwd>
<kwd lng="es"><![CDATA[hiperuricemia]]></kwd>
<kwd lng="es"><![CDATA[hipertensión]]></kwd>
<kwd lng="es"><![CDATA[alopurinol]]></kwd>
<kwd lng="en"><![CDATA[Uric acid]]></kwd>
<kwd lng="en"><![CDATA[Hyperuricemia]]></kwd>
<kwd lng="en"><![CDATA[Hypertension]]></kwd>
<kwd lng="en"><![CDATA[Allopurinol]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<collab>Cecil &amp; Goldman</collab>
<source><![CDATA[Medicine]]></source>
<year>2015</year>
<edition>25</edition>
<page-range>1742</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McCrudden]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<source><![CDATA[Uric acid: the chemistry, physiology and pathology of uric acid and the physiologically important purine bodies, with a discussion of the metabolism in gout]]></source>
<year>1905</year>
<publisher-name><![CDATA[Paul Hoeber Medical Books]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Preitner]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bonny]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Laverriere]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Glut is a major regulator of uratehomeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy]]></article-title>
<source><![CDATA[Proc Natl Acad Sci USA]]></source>
<year>2009</year>
<volume>106</volume>
<numero>36</numero>
<issue>36</issue>
<page-range>15501-6</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hediger]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Miyazaki]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Endou]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular physiology of urate transport]]></article-title>
<source><![CDATA[Physiology (Bethesda)]]></source>
<year>2005</year>
<volume>20</volume>
<page-range>125-33</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yan Miao]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of a reduction in uric acid on renal outcomes during losartan treatment a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the angiotensin II antagonist losartan trial]]></article-title>
<source><![CDATA[Hypertension J]]></source>
<year>2012</year>
<volume>1</volume>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wright]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Rudan]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Hastie]]></surname>
<given-names><![CDATA[ND]]></given-names>
</name>
<name>
<surname><![CDATA[Campbell]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A ´complexity´ of urate transporters]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>2010</year>
<volume>78</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>446-52</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alvarez-Lario]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Macarron-Vicente]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uric acid and evolution]]></article-title>
<source><![CDATA[Rheumatology (Oxford)]]></source>
<year>2010</year>
<volume>49</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2010-5</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="">
<collab>American College of Rheumatology</collab>
<source><![CDATA[Guidelines for Management of Gout. Part 2: Therapy and Antiinflammatory Prophylaxis of Acute Gouty Arthritis]]></source>
<year>2012</year>
<volume>64</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1447-61</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bobulescu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Renal transport of uric acid: evolving concepts and uncertainties ion]]></article-title>
<source><![CDATA[Adv Chronic Kidney Dis]]></source>
<year>2012</year>
<volume>19</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>358-71</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sakhaee]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Adams-Huet]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Moe]]></surname>
<given-names><![CDATA[OW]]></given-names>
</name>
<name>
<surname><![CDATA[Pak]]></surname>
<given-names><![CDATA[CY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathophysiologic basis for normouricosuric uric acid nephrolithiasis]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>2002</year>
<volume>62</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>971-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Why focus on uric acid]]></article-title>
<source><![CDATA[Curr Med Res Opin]]></source>
<year>2015</year>
<volume>31</volume>
<numero>Suppl 2</numero>
<issue>Suppl 2</issue>
<page-range>3-7</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Qin]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hyperuricemia and risk of incident hypertension A systematic review and meta-analysis of observational studies]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2014</year>
<volume>9</volume>
<numero>12</numero>
<issue>12</issue>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mazzali]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hughes]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[YG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism]]></article-title>
<source><![CDATA[Hypertension]]></source>
<year>2001</year>
<volume>38</volume>
<page-range>1101-6</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sanchez-Lozada]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
<name>
<surname><![CDATA[Tapia]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez-Molina]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of acute and chronic L-arginine treatment in experimental hiperuricemia]]></article-title>
<source><![CDATA[Am J Physiol Renal Physiol]]></source>
<year>2007</year>
<volume>292</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>F1238-44</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kanellis]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Watanabe]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2]]></article-title>
<source><![CDATA[Hypertension]]></source>
<year>2003</year>
<volume>41</volume>
<page-range>1287-93</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Feig]]></surname>
<given-names><![CDATA[DI]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hyperuricemia in childhood primary hypertension]]></article-title>
<source><![CDATA[Hypertension]]></source>
<year>2003</year>
<volume>42</volume>
<page-range>247-52</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Feig]]></surname>
<given-names><![CDATA[DI]]></given-names>
</name>
<name>
<surname><![CDATA[Soletsky]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension a randomized trial]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2008</year>
<volume>300</volume>
<page-range>924-32</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lapsia]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Dass]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Elevated uric acid increases the risk for acute kidney injury]]></article-title>
<source><![CDATA[Am J Med]]></source>
<year>2012</year>
<volume>125</volume>
<numero>302</numero>
<issue>302</issue>
<page-range>e309-17</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hovind]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rossing]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Tarnow]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes an inception cohort study]]></article-title>
<source><![CDATA[Diabetes]]></source>
<year>2009</year>
<volume>58</volume>
<page-range>1668-71</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Nakagawa]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Feng]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A role for uric acid in the progression of renal disease]]></article-title>
<source><![CDATA[J Am Soc Nephrol]]></source>
<year>2002</year>
<volume>13</volume>
<page-range>2888-97</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sanchez-Lozada]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
<name>
<surname><![CDATA[Soto]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Tapia]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia]]></article-title>
<source><![CDATA[Am J Physiol]]></source>
<year>2008</year>
<volume>295</volume>
<page-range>F1134-41</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="book">
<source><![CDATA[Allopurinol enhances the blood pressure lowering effect of enalapril in children with hyperuricemic essential hypertension Farahnak Assadi]]></source>
<year>2013</year>
<publisher-name><![CDATA[Italian Society of Nephrology]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wurzner]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gerster]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Chiolero]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mallard]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fallab Stubi]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative effects of losartan and irbesartan on serum uric acid un hypertensive patients with hyperuricaemia and gout]]></article-title>
<source><![CDATA[J Hypertens]]></source>
<year>2001</year>
<volume>19</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1855-60</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[IK]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uric acid-induced C-reactive protein expression implication on cell proliferation and nitric oxide production of human vascular cells]]></article-title>
<source><![CDATA[J Am Soc Nephrol]]></source>
<year>2005</year>
<volume>16</volume>
<page-range>3553-62</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Waring]]></surname>
<given-names><![CDATA[WS]]></given-names>
</name>
<name>
<surname><![CDATA[Adwani]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Breukels]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Webb]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Maxwell]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hyperuricaemia does not impair cardiovascular function in healthy adults]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2004</year>
<volume>90</volume>
<page-range>155-9</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Price]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Human vascular smooth muscle cells express a urate transporter]]></article-title>
<source><![CDATA[J Am Soc Nephrol]]></source>
<year>2006</year>
<volume>17</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1791-5</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hyperuricemia and risk of incident hypertension: A systematic review and meta-analysis of observational studies]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2014</year>
<volume>9</volume>
<numero>12</numero>
<issue>12</issue>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mazzali]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hyperuricemia exacerbates chronic cyclosporine nephropathy]]></article-title>
<source><![CDATA[Transplantation]]></source>
<year>2001</year>
<volume>71</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>900-5</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yui-Pong]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level]]></article-title>
<source><![CDATA[Am J Kidney Dis]]></source>
<year>2006</year>
<volume>47</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>51-9</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jun-Xia]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<source><![CDATA[Uric acid induces oxidative stress via an activation of the renin-angiotensin system in 3T3-L1 adipocytes]]></source>
<year>2013</year>
<publisher-name><![CDATA[Springer]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perlstein]]></surname>
<given-names><![CDATA[TS]]></given-names>
</name>
<name>
<surname><![CDATA[Gumieniak]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Hopkins]]></surname>
<given-names><![CDATA[PN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uric acid and the state of the intrarenal renin-angiotensin system in humans]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>2004</year>
<volume>66</volume>
<page-range>1465-70</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rao]]></surname>
<given-names><![CDATA[GN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression]]></article-title>
<source><![CDATA[J Biol Chem]]></source>
<year>1991</year>
<volume>266</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>8604-8</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chao]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uric acid stimulates endothelin-1 gene expression associated with NADPH oxidase in human aortic smooth muscle cells]]></article-title>
<source><![CDATA[Acta Pharmacol Sin]]></source>
<year>2008</year>
<volume>29</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1301-12</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
